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Abstract: 
Objective of present study involves preparation and evaluation of floating microballoons of 
Stavudine is a potent antiviral agent, used for treatment of human immunodeficiency virus (HIV) 
infection. In present study Stavudine was used as a model drug, to increase its residence time in 
the stomach without contact with the mucosa. The microballoonswere prepared by the emulsion 
solvent diffusion technique using different ratio of polymers (Eudragit S100, Ethyl cellulose and 
PVP K 30) as carriers. The yield of microballoons was up to 68.32-80.22 %. 
The cumulative percent drug release after 24 hrs of the Stavudine microballoons was in the range 
of 53.62 to 87.45 %.   
Keywords: Stavudine, floating microballoons, floating drug delivery system, emulsion solvent 
diffusion method. 
 
INTRODUCTION 
The main purpose of any drug delivery system is effectivecontrol of disease, minimum side 
effects and better patient compliance in the cost effective way
1
. 
Dosage forms retained in the stomach are called gastro retentive drug delivery systems. 
Gastroretentive drug delivery is an approach to prolong gastric residence time, thus targeting 
site-specific drug release in the upper gastrointestinal tract for local or systemic effects. 
Gastroretentive dosage forms can remain in the gastric region for long periods and hence prolong 
the gastric retention time of drugs
2
. 
Floating drug delivery systems have a bulk density lower than gastric fluids and thus remain 
buoyant in stomach for a prolonged period of time, without affecting the gastric emptying rate
3
. 
Microballons, refer to hollow microsphere is gastro-retentive drug delivery based non-
effervescent approach. They are spherical empty particles without core made up of synthetic 
polymers or natural proteins, ideally having a size less than 200 μm. They floats immediately 
upon contact with gastric fluid and gives promising approaches for increasing the bioavailability 
of drugs with absorption windows in upper small intestine and stomach
4
.  
Stavudine is a potent antiviral agent belongs to the class ofnucleoside reverse transcriptase 
inhibitors. It is used along with other drugs for treatment of human immunodeficiency virus 
(HIV) infection. It decreases the amount of HIV in blood
5,6,7
. 
Moreover use of Stavudine is associated with many limitations such as adverse  effects due to 
accumulation of drug during multi dose therapy, poor patient compliance, and high cost
8,9
. 
The objective of the present study was to prepare floatingmicroballoons  of Stavudine to 
overcome these problems and to increase its gastric residence time in the stomach, consequently 
enhance its bioavailability and increase patient compliance. 
MATERIALS AND METHODS 
Stavudine was received as gift sample from ASPEN Pharmacare NIG. LTD, Eudragit S 100 from 
BOLAR Pharmaceuticals Ltd, and EC from Drugfield Pharmaceuticals Ltd. All other chemicals 
were of analytical grade. 
 DEVELOPMENT OF FLOATING MICROBALLOONS OF STAVUDINE BY 
EMULSION SOLVENT DIFFUSION METHOD
 
Stavudine floating microballoons were prepared by emulsion solvent diffusion method
10
. 200 mg 
Stavudine and polymers in different ratio were mixed in ethanol by using blending solvent 
dichloromethane and heavy liquid paraffin. The slurry was introduced into 250 ml beaker 
containing 0.2% Tween 80. The stirring was done for 2 h at 1000-1200 rpm by mechanicalstirrer 
equipped with four bladed propellers, to evaporate the volatile solvent. After evaporation of 
solvent, microballoons were collected by filtration, washed with water and dried at room 
temperature in a desiccator for 24 h. 
 
Table-1: Composition of floating microballoons formulations of Stavudine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EVALUATION PARAMETERS OF FLOATING MICROBALLOONS OF STAVUDINE  
1. % Yield of microballoons: Percentage yield of microballoons was calculated using the 
following formula 
11
. 
                                              
2. Microballoons size: The size was measured using an optical microscope and the mean 
microballoons diameter was calculated by measuring 100 particles with the help of a calibrated 
ocular micrometer12.
 
3.  Sphericity of the microballoons: 
Sphericity, of prepared microballoons were taken on a black paperusing camera lucida
13
.  
Circulatory factor (S) was calculated using,                                                                                                                      
S= P^2/(12.56×A) 
Where A is area (cm
2
) and, P is the perimeter of the circular tracing  
4. Drug entrapment efficiency
14
:  
Accurately weighed 10 mg of crushed microballoons were dissolved in 0.1N HCl, and then 
transferred to 100 ml volumetric flask. The volume was made up to 100mL with 0.1N HCl. The 
solution was filtered using Whatman filter paper no. 41. The samples were assayed for drug 
content using UV spectrophotometry at 265 nm. 
The amount of drug entrapped in the microballoons was calculated by the following formula: 
DEE =(Amount of drug actually present )/( Theoretical drug load expected) X100 
Batch 
code 
Eudragit 
S100 
(mg) 
EC 
(mg) 
PVP Tween 
80 
(mg) 
Di-chloromethane 
:Ethanol 
::1:1  
Liquid 
Paraffin 
(ml) 
MB1 200 - - 5 - 50 
MB2 - 200 - 5 - 50 
MB3 100 200 - - 10 - 
MB4 200 100 - - 10 - 
MB5 - 200 100 5 - 50 
MB6 - 100 200 5 - 50 
MB7 100 - 200 - 10 - 
MB8 200 - 100 - 10 - 
 5. Assessment of in-vitro buoyancy
15
: 
The floating microballoons about 100 mg were spread over the surface of the dissolution 
medium of 900 ml simulated gastric fluid (SGF, pH 2.0), which is placed in USP dissolution 
apparatus II. 
The medium temperature was maintained at 37 °C and was agitated by paddle at 100 rpm. After 
agitation the microballoons that floated over the surface of the medium and those that settled 
down at bottom of the flask were recovered separately and dried. The percentage of floating 
microballoons was determined by the following equation:                    
Buoyancy (%) =(WF )/( WF+WS ) X100 
Where WF  and WS are the weight of floating and settled microballoons respectively. 
6.  In-vitro drug release studies:  
The in-vitro dissolution studies were carried out by using USP II paddle type dissolution 
apparatus. Accurately 100mg of  microballoons was introduced into 900 ml of 0.1 N Hcl (pH 2), 
used as a dissolution medium, maintained at a temperature of 37°C, and a rotational speed of 100 
rpm. Samples were withdrawn at predetermined time intervals of every one hour for twelve 
hours. The samples were analyzed UV spectrophotometrically at 265 nm to determine the 
percentage of drug release
16
.  
 
RESULTS AND DISCUSSION- 
8 floating microballoons formulations of Stavudine were prepared by using different polymers 
i.e. Eudragit S100, EC and PVP K30, in different ratio by emulsion solvent diffusion method.  
The mean particle diameter of the microballoons was between 230.23-238.33 µm. In general  as 
the polymer concentration increases, the particle size also increases. This is because the viscosity 
of the polymer solution increases with increasing polymer concentration, which in turn decreases 
the stirring efficiency.  
The sphericity factor obtained for the microballoons lies in the range of 1.04-1.14. The sphericity 
value nearer to 1 indicates that the prepared formulations were spherical in nature.  
High incorporation efficiencies are seen with lower concentrations of polymer with the drug.  
The percentage entrapment efficiency of the microballoons was between 74.64-85.37%.   
The percentage yield of the microballoons was between 68.32-80.22%.  
The purpose of preparing floating microballoons was to extend the gastric residence time of a 
drug. The floating ability test was carried out to investigatethe floatability of the prepared 
microballoons. The mean percentage buoyancy of the microballoons was between 69.23-82.53 
%. In-vitro buoyancy studies reveal that in spite of stirring the dissolution medium for more 
than 12 hrs formulations were still continued to float without any apparent gelation, thus 
indicating that microballoons exhibit excellent buoyancies which can be attributed to the pores 
and cavities present in them. 
 In general with increase in the amount of polymers there is an increase in the buoyancy 
percentage. The increase in the buoyancy percentage may be attributed to air which caused 
swelling because of increased amount of the polymers present. The good buoyancy behavior of 
the microballoons may be attributed to the hollow nature ofthe microballoons. 
The cumulative percent drug release after 24 hrs of the Stavudine microballoons was 53.62 to 
87.45 %.  Maximum percent release was shown by formulation containing Eudragit S 100 and 
Ethylcellulose of batch MB4. It was also observed that the drugrelease generally decreased as 
the polymer ratio increased. The release of the drug was retarded due to the hydrophobic and 
 insoluble nature of the polymers used.  The increased density of the polymer matrix at higher 
concentrations results in an increased diffusion path length. This may decrease the overall drug 
release from the polymer matrix. Furthermore, smaller microballoons are formed at a lower 
polymer concentration and have a larger surface area exposed to dissolution medium, giving 
rise to faster drug release. 
STATISTICAL ANALYSIS 
Experimental results were expressed as mean ± SD. Student’s t-test and one-way analysis of 
variance (ANOVA) were applied to check significant differences in drug release from different 
formulations. Differences were considered to be statistically significant at p < 0.05. 
CONCLUSION- 
In present study 8 different Stavudine floating microballoons formulations were prepared with a 
view of improving its oral bioavailability and giving a prolongedrelease of drug. The 
microballoons shows satisfactory yield and impressive drug entrapment efficiency. Release 
properties were satisfactory and the formulations hold promise for further development into drug 
delivery systems for oral administration of Stavudine. 
In vitro drug release studies showed that the drug release was more in case of formulations MB4. 
Stavudine floating microballoons formulations of batch MB4 was concluded as the optimum 
formulations among the all 8 formulations based on different parameters. 
However there is need in-vivo study to justify the development of Stavudine floating 
microballoons. 
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Table-2: Characterization of floating microballoons formulations of Stavudine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Batch 
Code 
Particle 
Size (µm) 
Sphericity Yield (%) Entrapment 
Efficiency (%) 
% Buoyancy 
MB1 230.23±0.35 1.08±0.04 70.34±0.05 80.52±0.23 69.23±0.21 
MB2 235.53±0.24 1.11±0.13 68.32±0.08 79.64±0.41 74.46±0.12 
MB3 228.12±0.31 1.09±0.09 66.46±0.41 83.37±0.52 75.84±0.21 
MB4 230.21±0.18 1.07±0.06 80.22±0.63 85.37±0.13 82.53±0.12 
MB5 234.12±0.27 1.04±0.21 79.44±0.53 79.64±0.29 73.46±0.21 
MB6 235.16±0.22 1.08±0.11 75.46±0.22 75.64±0.31 76.46±0.17 
MB7 236.21±0.13 1.14±0.41 78.46±0.51 74.64±0.42 77.46±0.32 
MB8 239.33±0.33 1.11±0.32 75.46±0.32 78.64±0.53 78.46±0.33 
  
Fig-1:  Percentage drug released from microballoons of batch MB1 to MB4 
 
 
 
Fig-2:  Percentage drug released from microballoons of batch MB5 to MB8 
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